Former electroCore executive Daniel S. Goldberger has executed a significant divestment of company stock, selling 80,000 shares of common equity for a total realized value of $544,000. The transaction, initially reported on April 23, 2026, involved a weighted average sale price of $6.80 per share. Footnote details within the filing reveal that the liquidation was not a single event but rather a series of transactions executed between April 23, 2026, and May 26, 2026. During this window, shares were disposed of at varying prices, ranging from a low of $6.00 to a high of $8.52 per share.
Following the completion of these sales, Goldberger retains a direct holding of 211,471 shares in electroCore. The filing explicitly identifies him as a former officer and director, distinguishing his current status from active management roles. The timing of this sale is notable given the recent market performance of the stock. ECOR is currently trading at $10.25, a level that represents a substantial appreciation from Goldberger's weighted average exit price and places the share price near its 52-week high of $10.45. This upward trajectory is part of a broader trend, with the stock delivering a 128% return year-to-date, according to available data.
While executive insider selling often draws scrutiny, it occurs against a backdrop of reported operational milestones for electroCore. The company recently announced record-breaking revenue for the first quarter of 2026. Net sales reached $9.6 million, marking a 43% increase compared to the same period in the previous year. However, this top-line growth was accompanied by a widening bottom-line deficit. The company reported a GAAP net loss of $5.3 million, an increase from the $3.9 million loss recorded in the first quarter of 2025. These financial figures underscore the ongoing challenges in translating revenue growth into profitability.
Beyond financial results, electroCore continues to advance its clinical research initiatives. The company is involved in a study published in JAMA Network Open that examines the efficacy of a modified Quell device for the treatment of fibromyalgia. This clinical trial evaluated the device when used in conjunction with outpatient physical therapy. The study enrolled 384 participants, providing data on the potential therapeutic applications of the technology. These developments highlight the company's focus on both commercial growth and clinical validation of its products.